Today, fool.com health-care analysts David Williamson and Brenton Flynn look at one of the most popular and controversial stocks in health care, Dendreon.
Favorable news about insurance coverage sent shares of the company about 10% higher today, but they eventually retreated a bit by market close.
Investors are increasingly seeing insurers being a major driver of biotech stocks everywhere, with the decision to insure or not being a make-it-or-break-it moment for those companies. Today Dendreon got a big break, but this is hardly the sort of decision investors can bank on.
Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.
Brenton Flynn and Dave Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.
Is Johnson & Johnson a Buy?
Is now a good time to invest in the healthcare titan's stock?